SETH LERNER to Doxorubicin
This is a "connection" page, showing publications SETH LERNER has written about Doxorubicin.
Connection Strength
0.533
-
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
Score: 0.438
-
Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. Urol Oncol. 2003 May-Jun; 21(3):197-205.
Score: 0.048
-
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
Score: 0.021
-
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009 Sep 15; 115(18):4104-9.
Score: 0.019
-
Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Jun; 9(6):943-5.
Score: 0.007